Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $6,964 | 1 | 61.9% |
| Travel and Lodging | $2,283 | 8 | 20.3% |
| Unspecified | $1,104 | 3 | 9.8% |
| Food and Beverage | $895.75 | 16 | 8.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Research & Development, LLC | $6,964 | 1 | $0 (2017) |
| Eisai Inc. | $2,443 | 18 | $0 (2019) |
| Eli Lilly and Company | $980.00 | 2 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $712.66 | 4 | $0 (2017) |
| AbbVie, Inc. | $124.18 | 1 | $0 (2019) |
| Allergan Inc. | $23.95 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $660.00 | 1 | Eli Lilly and Company ($660.00) |
| 2020 | $320.00 | 1 | Eli Lilly and Company ($320.00) |
| 2019 | $1,508 | 13 | Eisai Inc. ($1,384) |
| 2018 | $1,058 | 6 | Eisai Inc. ($1,058) |
| 2017 | $7,700 | 7 | Janssen Research & Development, LLC ($6,964) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $660.00 | Research |
| Study: ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | ||||||
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $320.00 | Research |
| Study: ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | ||||||
| 12/06/2019 | AbbVie, Inc. | — | — | In-kind items and services | $124.18 | Research |
| Study: M15-566 | ||||||
| 12/05/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $50.60 | General |
| 08/12/2019 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $597.73 | General |
| 08/12/2019 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $186.67 | General |
| 08/12/2019 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $131.75 | General |
| 08/12/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $124.95 | General |
| 08/12/2019 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $83.67 | General |
| 08/12/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $58.87 | General |
| 08/12/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| 08/12/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $49.98 | General |
| 08/12/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $24.99 | General |
| 08/12/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $12.48 | General |
| 08/12/2019 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $12.48 | General |
| 05/08/2018 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $626.02 | General |
| 05/08/2018 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $179.67 | General |
| 05/08/2018 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $109.48 | General |
| 05/08/2018 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $48.66 | General |
| 05/08/2018 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $48.66 | General |
| 05/08/2018 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $45.95 | General |
| 11/16/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Travel and Lodging | In-kind items and services | $232.96 | General |
| 11/16/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Food and Beverage | In-kind items and services | $114.99 | General |
| 11/15/2017 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $245.00 | General |
| 11/15/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Food and Beverage | In-kind items and services | $119.71 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | Eli Lilly and Company | $980.00 | 2 |
| M15-566 | AbbVie, Inc. | $124.18 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 152 | 185 | $59,937 | $18,288 |
| 2022 | 7 | 221 | 313 | $79,795 | $24,262 |
| 2021 | 9 | 280 | 410 | $92,476 | $29,168 |
| 2020 | 9 | 318 | 447 | $98,697 | $29,856 |
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 32 | 32 | $17,315 | $4,676 | 27.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $17,292 | $4,277 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 37 | 44 | $10,659 | $3,547 | 33.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 26 | 26 | $8,078 | $3,226 | 39.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 42 | $6,594 | $2,563 | 38.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 88 | $19,976 | $6,938 | 34.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 44 | 78 | $12,246 | $4,222 | 34.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 16 | 16 | $7,004 | $2,547 | 36.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 26 | 26 | $10,752 | $2,407 | 22.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 17 | 17 | $7,871 | $1,996 | 25.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 34 | 38 | $8,872 | $1,990 | 22.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $5,698 | $1,649 | 28.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 25 | 25 | $4,400 | $1,350 | 30.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 12 | 12 | $2,976 | $1,162 | 39.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 66 | 159 | $24,963 | $8,728 | 35.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 36 | 68 | $15,436 | $5,406 | 35.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 54 | 59 | $13,275 | $4,090 | 30.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 16 | $6,848 | $2,546 | 37.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 26 | 26 | $10,452 | $2,292 | 21.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 14 | 14 | $6,154 | $2,005 | 32.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 18 | 18 | $6,066 | $1,700 | 28.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 24 | 24 | $4,224 | $1,324 | 31.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 15 | $3,375 | $605.34 | 17.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 11 | 11 | $1,683 | $470.70 | 28.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 81 | 196 | $30,772 | $11,044 | 35.9% |
About Dr. Gregory Jicha, MD
Dr. Gregory Jicha, MD is a Neurology healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1619073202.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Jicha, MD has received a total of $11,247 in payments from pharmaceutical and medical device companies, with $660.00 received in 2022. These payments were reported across 28 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($6,964).
As a Medicare-enrolled provider, Jicha has provided services to 971 Medicare beneficiaries, totaling 1,355 services with total Medicare billing of $101,574. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location Lexington, KY
- Active Since 09/15/2006
- Last Updated 05/02/2022
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1619073202
Products in Payments
- CNP520 (Drug) $467.66
- NAMZARIC (Drug) $23.95
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Lexington
Dr. Nicole Everman, M.d, M.D
Neurology — Payments: $506,986
Toufic Fakhoury, Md, MD
Neurology — Payments: $393,864
Larry Goldstein, Md, MD
Neurology — Payments: $28,134
Jagannadha Avasarala, Md, Phd, MD, PHD
Neurology — Payments: $26,770
Fred Odago, Md, MD
Neurology — Payments: $22,752
Sharoon Qaiser, M.d, M.D
Neurology — Payments: $19,615